Phio Pharmaceuticals (PHIO) Total Liabilities (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Total Liabilities came in at $950000.0 in Q1 2026, down 25.2% YoY from $1.3 million in Q1 2025, and down 29.1% on a QoQ basis from $1.3 million in Q4 2025.
Phio Pharmaceuticals (PHIO) Total Liabilities (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Total Liabilities data on file, last reported at $950000.0 in Q1 2026.
- Quarterly Total Liabilities fell 25.2% year-over-year to $950000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $950000.0 (down 25.2% YoY) and the FY2025 annual result came in at $1.3 million, up 32.02% from the prior year.
- Total Liabilities fell to $950000.0 in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $5.9 million in Q3 2024 to a low of $950000.0 in Q1 2026.
- A 5-year average of $2.5 million and a median of $2.3 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities surged 152.15% — and 2025, when it tumbled 77.87%.
- Tracing PHIO's Total Liabilities over 5 years: stood at $2.0 million in 2022, then slipped by 17.22% to $1.6 million in 2023, then sank by 37.88% to $1.0 million in 2024, then soared by 32.02% to $1.3 million in 2025, then dropped by 29.1% to $950000.0 in 2026.
- The last three Total Liabilities figures came in at $950000.0 (Q1 2026), $1.3 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | 1.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.71 Mn |
| Mar 31, 2026 | 950,000.00 |
| Dec 31, 2025 | 1.34 Mn |
| Sep 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 5.87 Mn |
| Jun 30, 2024 | 5.30 Mn |
| Mar 31, 2024 | 5.74 Mn |
| Dec 31, 2023 | 1.63 Mn |
| Sep 30, 2023 | 2.33 Mn |
| Jun 30, 2023 | 2.39 Mn |
| Mar 31, 2023 | 2.40 Mn |
| Dec 31, 2022 | 1.97 Mn |
| Sep 30, 2022 | 2.26 Mn |
| Jun 30, 2022 | 3.14 Mn |
| Mar 31, 2022 | 2.71 Mn |
| Dec 31, 2021 | 3.24 Mn |
| Sep 30, 2021 | 2.70 Mn |